LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Lenz Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.796 Good afternoon, ladies and gentlemen, and welcome to the Lens Therapeutic 00:00:04.796 -- 00:00:09.201 third quarter 2025 financial results conference call. 00:00:09.201 -- 00:00:13.305 At this time, all participants are in a listen-only mode. 00:00:13.305 -- 00:00:19.032 Following prepared remarks from management, we'll conduct a question and answer session, 00:00:19.032 -- 00:00:21.795 and instructions will follow at that time. 00:00:21.795 -- 00:00:24.247 As a reminder, this call is being recorded. 00:00:24.247 -- 00:00:29.292 At this time, I'd like to turn the call over to Dan Chevalard, Chief Financial 00:00:29.292 -- 00:00:30.654 Officer. Please go ahead. 00:00:30.654 -- 00:00:32.654 Thank 00:00:33.316 -- 00:00:36.600 you. Good morning, and thank you for joining us today. 00:00:36.600 -- 00:00:41.405 My name is Dan Chevalard, Chief Financial Officer of Lens Therapeutics. 00:00:41.405 -- 00:00:46.450 I'm joined today by Abe Skilfenick, President and Chief Executive Officer, and Sean 00:00:46.450 -- 00:00:49.493 Olson, Chief Commercial Officer, as well as Dr. 00:00:49.493 -- 00:00:55.730 Mark Odrich, Chief Medical Officer who will join us for the question and answer session. 00:00:55.730 -- 00:00:59.554 Before we begin, I would like to remind you that this call will contain forward-looking 00:00:59.554 -- 00:01:03.518 statements regarding LINSA's future expectations, 00:01:03.518 -- 00:01:09.824 plans, prospects, corporate strategy, regulatory and commercial plans and expectations, 00:01:09.824 -- 00:01:12.868 cash runway projections and performance. 00:01:12.868 -- 00:01:17.752 Actual results may differ materially from those indicated by these forward-looking statements 00:01:17.752 -- 00:01:22.949 as a result of various impor...